Form 4: Protara Therapeutics VP, Controller Hannah Fry Reports Acquisition of Shares and Stock Options

Hannah Fry, VP, Controller of Protara Therapeutics, reports the acquisition of 9,500 shares of common stock and 55,000 stock options.

Summary

• On January 24, 2025, Hannah Fry, VP, Controller of Protara Therapeutics, acquired 9,500 shares of common stock through restricted stock units (RSUs).
• These RSUs vest in equal one-third installments annually, starting January 24, 2025.
• Fry also acquired 55,000 stock options with an exercise price of $4.53.
• 25% of these options vest on January 24, 2025, with the remaining options vesting monthly over the subsequent three years, contingent upon continuous service.
• Following these transactions, Fry directly owns 38,942 shares of common stock and 55,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine stock and option grants. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The acquisition of shares and stock options by a company officer can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person's continuous service with the Issuer.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders due to potential dilution from the issuance of new shares upon vesting of RSUs and exercise of stock options.

Key Dates